相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Respiratory System
Dennis Thomas et al.
Summary: This review discusses the definitions, prevalence, predictors, pathophysiology, treatment possibilities, and research directions of asthma remission. Remission is characterized by high level of disease control and normalized or optimized lung function. Even in symptomatic remission, persistent pathological abnormalities and risk of relapse exist. The prevalence of remission varies between 2% and 52% in adult asthma population. Factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities, and smoking cessation or never smoking. Current long-term add-on therapies can achieve some criteria for remission in a subgroup of patients. Further research is required to evaluate remission as a treatment goal.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Review
Allergy
Hideaki Morita et al.
Summary: Biologics or molecularly targeted drugs are highly effective and relatively safe for the treatment of allergic and immunologic diseases. Recent clinical trials have demonstrated their effectiveness and revealed unexpected findings, contributing to an improved understanding of the pathophysiology of these disorders.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Review
Allergy
Pauline Azzano et al.
Summary: The advent of biologic therapies has revolutionized the treatment of severe atopic disorders, but their high cost presents challenges in terms of long-term sustainability and resource allocation. Utilizing economic analyses can help guide decision-making and prioritization in care, but the conclusions regarding cost-effectiveness of biologic drugs in atopic disorders vary due to inconsistent estimates of health utility benefit. Developing reliable instruments to measure disutility in atopic disorders and indirect costs in atopic diseases is identified as a priority for future research.
Review
Allergy
Thanaporn Ratchataswan et al.
Summary: Atopic dermatitis is a common inflammatory skin disease characterized by intense itching and recurrent eczema lesions. The development of targeted biologic therapies, such as Dupilumab, is highly desirable for the treatment of moderate-to-severe forms of AD.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Review
Allergy
Amber N. Pepper et al.
Summary: Five biologic medications approved for treating uncontrolled asthma target elevated type 2 inflammatory markers like eosinophils, nitric oxide, or IgE. Factors such as asthma severity, biomarkers, and treatment goals should guide initial biologic choice, with shared decision-making with patients to optimize adherence. Monitoring response and troubleshooting are essential for patients with suboptimal responses, with potential need for changing biologic therapy or exploring other treatment options.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Review
Allergy
Marcus Maurer et al.
Summary: The guidelines recommend the use of omalizumab in antihistamine-refractory CSU, highlighting the key role of IgE and FcεRI in the pathogenesis. The review covers mechanisms of action, biomarkers, and strategies for improving treatment efficacy, as well as exploring off-label use of other biologics. Future directions include novel biologics targeting various pathways in CSU treatment.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Review
Allergy
Yoshimichi Okayama et al.
ALLERGOLOGY INTERNATIONAL
(2020)
Review
Medicine, Research & Experimental
Marie Godar et al.
Article
Medicine, General & Internal
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL
(2017)
Article
Medicine, General & Internal
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL
(2017)
